WHY IT MATTERS: West Virginia medical cannabis patients who previously had limited delivery options may soon be able to access edible formulations, giving physicians and patients more tools to tailor treatment to individual medical needs. CLINICAL OVERVIEW: West Virginia’s expansion of its medical cannabis program to include edible formulations represents a meaningful step toward improving patient access and treatment flexibility. Edibles offer distinct pharmacokinetic advantages for certain patient populations, particularly those with respiratory conditions who cannot tolerate inhalation, or those requiring longer-duration symptom relief due to the slower onset and extended duration of orally administered cannabinoids.